Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ledipasvir/Sofosbuvir +/- Ribavirin in Egyptian Genotype 4 HCV
NCT02487030Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ledipasvir in hepatitis C virus infection (7 arms), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Discontinuation of Therapy and Percentage of Participants Who Discontinued LDV/SOF Drug Due to an Adverse Event at 12 weeks. Started Sep 2015; status: completed.
02
Drugs
ledipasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02487030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487030.